Citadel Advisors LLC Invests $389,000 in Oculis Holding AG (NASDAQ:OCS)

Citadel Advisors LLC acquired a new stake in shares of Oculis Holding AG (NASDAQ:OCS - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 22,911 shares of the company's stock, valued at approximately $389,000. Citadel Advisors LLC owned about 0.06% of Oculis as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of OCS. Bellevue Group AG purchased a new position in shares of Oculis during the 4th quarter valued at about $170,000. XTX Topco Ltd purchased a new position in shares of Oculis during the 4th quarter valued at about $225,000. Geode Capital Management LLC increased its stake in shares of Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock valued at $284,000 after purchasing an additional 1,800 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after purchasing an additional 10,667 shares in the last quarter. Finally, abrdn plc increased its stake in shares of Oculis by 23.0% in the 4th quarter. abrdn plc now owns 1,009,424 shares of the company's stock valued at $17,150,000 after purchasing an additional 188,871 shares in the last quarter. Hedge funds and other institutional investors own 22.30% of the company's stock.

Analyst Upgrades and Downgrades

OCS has been the subject of several recent analyst reports. HC Wainwright lifted their price target on Oculis from $29.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, April 17th. Chardan Capital boosted their price objective on Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Finally, Robert W. Baird boosted their price objective on Oculis from $37.00 to $41.00 and gave the stock an "outperform" rating in a research note on Thursday, March 13th.

Oculis Price Performance

NASDAQ:OCS traded up $0.36 during trading hours on Friday, hitting $19.92. 42,605 shares of the stock were exchanged, compared to its average volume of 44,451. Oculis Holding AG has a 52-week low of $10.79 and a 52-week high of $23.08. The firm's fifty day moving average price is $17.91 and its 200 day moving average price is $18.71. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The company has a market cap of $869.75 million, a P/E ratio of -10.32 and a beta of 0.35.

Oculis (NASDAQ:OCS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.22 million. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. As a group, equities research analysts anticipate that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Oculis Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.